FIVE at FIVE AU: ASX slips; banks underperform

Published 10/01/2025, 03:39 pm
Updated 10/01/2025, 04:00 pm
© Reuters.  FIVE at FIVE AU: ASX slips; banks underperform
AXJO
-
DBKGn
-
CBA
-
ANZ
-
NAB
-
MS
-
WBC
-

The ASX 200 is trading lower for a second straight day, down 0.5% this afternoon. The Financials and Consumer Staples sectors are each down more than 1%, while the Materials sector is up.

The major banks are each trading lower. Westpac is the worst of the lot, down 1.9% after it was downgraded by Morgan Stanley (NYSE:NYSE:MS) to underweight. The broker lifted its rating for ANZ to equal-weight but it is also down 0.4% today, while Australia’s largest bank CBA is down 1.6%.

February rate cut tipped

ANZ now predicts the RBA will cut the cash rate by 25 basis points at its February meeting — earlier than its previous May prediction.

This shift in expectations follows weaker-than-expected consumer price growth data, which suggests the RBA’s preferred trimmed mean inflation measure will drop to 3.2%, below its 3.4% forecast.

Consumption data released Thursday also supports this case, with the ABS reporting a 0.4% rise in household spending — short of the anticipated 0.6%. Retail spending similarly underwhelmed, despite pre-Christmas sales promotions.

Comprehensive December quarter inflation data, due January 29, remains pivotal to the RBA’s decision. ANZ joins CBA in forecasting a February rate cut, while NAB and Westpac maintain a May prediction.

Bond markets now reflect a 78% probability of a February cut, up from 66% before the inflation data release.

Treasurer Jim Chalmers noted the shift in market sentiment but reiterated the RBA’s independence. Labor, ahead of the federal election, hopes for rate relief for borrowers impacted by 13 hikes since May 2022, which have lifted the cash rate to 4.35%.

ETFs achieve record inflows

VanEck’s December ETF Industry Pulse revealed that Australia’s exchange-traded funds (ETFs) industry achieved record-breaking growth in 2024.

Net flows for the month surged to nearly $4 billion, with Vanguard, BetaShares, iShares and VanEck capturing 96.4% of these flows.

For the year, total net flows reached $35 billion, surpassing the previous record of $23.2 billion set in 2021. The ETF market capitalisation also hit a historic high of $247 billion, for 38% year-on-year growth. The top four issuers accounted for 98.8% of net flows in 2024.

In response to the growing demand, fund managers launched 64 new ETFs across the ASX and CBOE, bringing the total number of exchange-traded products in Australia to over 400.

The surge was driven by international equities ETFs, which attracted over $15 billion in net flows, more than double that of Australian equities and far exceeding 2023’s trends.

VanEck anticipates continued robust growth ahead, projecting the ETF market cap to exceed $250 billion in early 2025 and reach $300 billion by year-end. This trajectory underscores the increasing popularity of ETFs among Australian investors.

Five at Five

Arovella Therapeutics fully funded to complete Phase 1 clinical trial for ALA-101

Arovella Therapeutics Ltd (ASX:ALA) has raised $20 million, including a $15 million cornerstone investment. The raise fully funds the completion and reporting of a Phase 1, first-in-human clinical trial for ALA-101 in patients with CD19-positive blood cancers,

Read more

European Lithium’s Critical Metals Corp an early adopter when it comes to Greenland’s unique potential

European Lithium Ltd (ASX:ASX:EUR, OTCQB:EULIF)’s wholly owned US subsidiary Critical Metals Corp. (Nasdaq: CRML) could have been accused of being prescient when it took a stake in Greenland’s Tanbreez Project, one of the world’s largest known deposits of rare earth elements.

Read more

Mako Resources directors urge shareholders to accept Aurum’s final takeover offer

The independent Mako Gold Ltd (ASX:MKG) board directors have unanimously recommended that the company’s shareholders accept the best and final offer from Aurum Resources Ltd (ASX:AUE) without delay.

Read more

Plastics waste fight gears up as ExxonMobil sues Andrew Forrest for ‘smear campaign’

Andrew Forrest has taken a ‘bring it on’ stance in response to ExxonMobil’s defamation lawsuit, which it has filed against Forrest’s Intergenerational Environment Justice Fund (IEJF), California Attorney-General Rob Bonta and several environmental groups.

Read more

European equities to outshine the US market in 2025, says Deutsche Bank (ETR:DBKGn)

Deutsche Bank anticipates a "tactical outperformance" of European stocks in 2025, citing improving macroeconomic data, lower interest rates and potential upside from China as key catalysts.

Read more

On your six

Infinity Asset Management’s top five investment themes for 2025

Infinity Asset Management has offered its top five investment themes for 2025, with a focus on growth.

Read more

One to watch

Mesoblast prepares to launch FDA-approved therapy for Pediatric Steroid-Refractory aGVHD

Mesoblast Ltd (NASDAQ:MESO, ASX:MSB) CEO Silviu Itescu joined Steve Darling from Proactive to share news the company has announced the U.S. Food and Drug Administration has approved remestemcel-L, now marketed under the brand name Ryoncil, as the first and only therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children.

Watch more

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.